Bladder and Ureter Cancer Drug Development Pipeline Review, 2017

  • ID: 4457570
  • Report
  • Region: Global
  • 150 Days
  • GBI Research
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • Bavarian Nordic A/S
  • Daiichi Sankyo Co Ltd
  • Immunomedics Inc
  • Moleculin Biotech Inc
  • Sanofi
  • MORE

Bladder and Ureter Cancer Drug Development Pipeline Review, 2017

Summary

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. There are a total of 223 products in development for this indication, by 158 companies and 19 academic institutions. Key companies active in this space include F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer.

Ureter or ureteral cancer affects the ureter, the tube that transports urine from the kidney to the urinary bladder. Symptoms and signs of the disease include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. There are a total of nine products in development for this indication, by six companies and two academic institutions.

These products act on a wide range of targets, including a number of growth factor receptors and intracellular signal transducers. Within bladder cancer, the most commonly developed targets are Programmed Cell Death 1 Ligand 1 and Tubulin.

The report "Bladder and Ureter Cancer Drug Development Pipeline Review, 2017" provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • Bavarian Nordic A/S
  • Daiichi Sankyo Co Ltd
  • Immunomedics Inc
  • Moleculin Biotech Inc
  • Sanofi
  • MORE

1 Table of Contents

2 Introduction
2.1 Bladder and Ureter Cancer Report Coverage
2.2 Ureter Cancer - Overview
2.3 Bladder Cancer - Overview

3 Therapeutics Development
3.1 Ureter Cancer
3.2 Bladder Cancer

4 Therapeutics Assessment
4.1 Ureter Cancer
4.2 Bladder Cancer

5 Companies Involved in Therapeutics Development
5.1 Ureter Cancer
5.2 Bladder Cancer

6 Dormant Projects
6.1 Bladder Cancer

7 Discontinued Products
7.1 Bladder Cancer

8 Product Development Milestones
8.1 Ureter Cancer
8.2 Bladder Cancer

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation

List of Tables
Table 1: Number of Products under Development for Ureter Cancer
Table 2: Number of Products under Development by Companies, Ureter Cancer
Table 3: Number of Products under Development by Universities/Institutes, Ureter Cancer
Table 4: Products under Development by Companies, Ureter Cancer
Table 5: Products under Development by Universities/Institutes, Ureter Cancer
Table 6: Number of Products under Development for Bladder Cancer
Table 7: Number of Products under Development by Companies, Bladder Cancer
Table 8: Number of Products under Development by Universities/Institutes, Bladder Cancer
Table 9: Products under Development by Companies, Bladder Cancer
Table 10: Products under Development by Universities/Institutes, Bladder Cancer
Table 11: Number of Products by Stage and Target, Ureter Cancer
Table 12: Number of Products by Stage and Mechanism of Action, Ureter Cancer
Table 13: Number of Products by Stage and Route of Administration, Ureter Cancer
Table 14: Number of Products by Stage and Molecule Type, Ureter Cancer
Table 15: Number of Products by Stage and Target, Bladder Cancer
Table 16: Number of Products by Stage and Mechanism of Action, Bladder Cancer
Table 17: Number of Products by Stage and Route of Administration, Bladder Cancer
Table 18: Number of Products by Stage and Molecule Type, Bladder Cancer
Table 19: Ureter Cancer - Pipeline by Altor BioScience Corp
Table 20: Ureter Cancer - Pipeline by Eisai Co Ltd
Table 21: Ureter Cancer - Pipeline by Exelixis Inc
Table 22: Ureter Cancer - Pipeline by GlaxoSmithKline Plc
Table 23: Ureter Cancer - Pipeline by MedImmune LLC
Table 24: Ureter Cancer - Pipeline by Merck & Co Inc
Table 25: Bladder Cancer - Pipeline by 4SC AG
Table 26: Bladder Cancer - Pipeline by Abivax SA
Table 27: Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc
Table 28: Bladder Cancer - Pipeline by ADC Therapeutics Sarl
Table 29: Bladder Cancer - Pipeline by Altor BioScience Corp
Table 30: Bladder Cancer - Pipeline by AndroScience Corp
Table 31: Bladder Cancer - Pipeline by ANP Technologies Inc
Table 32: Bladder Cancer - Pipeline by APIM Therapeutics AS
Table 33: Bladder Cancer - Pipeline by Archivel Farma SL
Table 34: Bladder Cancer - Pipeline by Argos Therapeutics Inc
Table 35: Bladder Cancer - Pipeline by Arno Therapeutics Inc
Table 36: Bladder Cancer - Pipeline by Array BioPharma Inc
Table 37: Bladder Cancer - Pipeline by Asana BioSciences LLC
Table 38: Bladder Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd
Table 39: Bladder Cancer - Pipeline by Astellas Pharma Inc
Table 40: Bladder Cancer - Pipeline by Astex Pharmaceuticals Inc
Table 41: Bladder Cancer - Pipeline by AstraZeneca Plc
Table 42: Bladder Cancer - Pipeline by AVEO Pharmaceuticals Inc
Table 43: Bladder Cancer - Pipeline by Bavarian Nordic A/S
Table 44: Bladder Cancer - Pipeline by Bayer AG
Table 45: Bladder Cancer - Pipeline by Biocad
Table 46: Bladder Cancer - Pipeline by BioCancell Ltd
Table 47: Bladder Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd
Table 48: Bladder Cancer - Pipeline by Biomics Biotechnologies Co Ltd
Table 49: Bladder Cancer - Pipeline by Biotest AG
Table 50: Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH
Table 51: Bladder Cancer - Pipeline by Bristol-Myers Squibb Co
Table 52: Bladder Cancer - Pipeline by Celgene Corp
Table 53: Bladder Cancer - Pipeline by Celldex Therapeutics Inc
Table 54: Bladder Cancer - Pipeline by Celprogen Inc
Table 55: Bladder Cancer - Pipeline by Celsion Corp
Table 56: Bladder Cancer - Pipeline by Celyad SA
Table 57: Bladder Cancer - Pipeline by Cleveland BioLabs Inc
Table 58: Bladder Cancer - Pipeline by Cold Genesys Inc
Table 59: Bladder Cancer - Pipeline by Corvus Pharmaceuticals Inc
Table 60: Bladder Cancer - Pipeline by CytomX Therapeutics Inc
Table 61: Bladder Cancer - Pipeline by Cytori Therapeutics Inc
Table 62: Bladder Cancer - Pipeline by Daiichi Sankyo Co Ltd
Table 63: Bladder Cancer - Pipeline by Eisai Co Ltd
Table 64: Bladder Cancer - Pipeline by Eleven Biotherapeutics Inc
Table 65: Bladder Cancer - Pipeline by Eli Lilly and Co
Table 66: Bladder Cancer - Pipeline by Elsalys Biotech SAS
Table 67: Bladder Cancer - Pipeline by EpiThany Inc
Table 68: Bladder Cancer - Pipeline by Esperance Pharmaceuticals Inc
Table 69: Bladder Cancer - Pipeline by Exelixis Inc
Table 70: Bladder Cancer - Pipeline by Exicure Inc
Table 71: Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd
Table 72: Bladder Cancer - Pipeline by Five Prime Therapeutics Inc
Table 73: Bladder Cancer - Pipeline by Gene Signal International SA
Table 74: Bladder Cancer - Pipeline by Genentech Inc

List of Figures
Figure 1: Number of Products under Development for Ureter Cancer
Figure 2: Number of Products under Development by Companies, Ureter Cancer
Figure 3: Number of Products under Development by Universities/Institutes, Ureter Cancer
Figure 4: Number of Products under Development for Bladder Cancer
Figure 5: Number of Products under Development by Companies, Bladder Cancer
Figure 6: Number of Products under Development by Universities/Institutes, Bladder Cancer
Figure 7: Number of Products by Top 10 Targets, Ureter Cancer
Figure 8: Number of Products by Stage and Top 10 Targets, Ureter Cancer
Figure 9: Number of Products by Top 10 Mechanism of Actions, Ureter Cancer
Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions, Ureter Cancer
Figure 11: Number of Products by Routes of Administration, Ureter Cancer
Figure 12: Number of Products by Stage and Top 10 Routes of Administration, Ureter Cancer
Figure 13: Number of Products by Molecule Types, Ureter Cancer
Figure 14: Number of Products by Stage and Molecule Types, Ureter Cancer
Figure 15: Number of Products by Top 10 Targets, Bladder Cancer
Figure 16: Number of Products by Stage and Top 10 Targets, Bladder Cancer
Figure 17: Number of Products by Top 10 Mechanism of Actions, Bladder Cancer
Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Bladder Cancer
Figure 19: Number of Products by Routes of Administration, Bladder Cancer
Figure 20: Number of Products by Stage and Routes of Administration, Bladder Cancer
Figure 21: Number of Products by Top 10 Molecule Types, Bladder Cancer
Figure 22: Number of Products by Stage and Top 10 Molecule Types, Bladder Cancer 56"

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4SC AG
  • ADC Therapeutics Sarl
  • ANP Technologies Inc
  • APIM Therapeutics AS
  • AVEO Pharmaceuticals Inc
  • Abivax SA
  • Adaptimmune Therapeutics Plc
  • Altor BioScience Corp
  • AndroScience Corp
  • Archivel Farma SL
  • Argos Therapeutics Inc
  • Arno Therapeutics Inc
  • Array BioPharma Inc
  • Asana BioSciences LLC
  • Asieris Pharmaceuticals Co Ltd
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Bayer AG
  • BioCancell Ltd
  • Biocad
  • Biohaven Pharmaceutical Holding Company Ltd
  • Biomics Biotechnologies Co Ltd
  • Biotest AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Celprogen Inc
  • Celsion Corp
  • Celyad SA
  • Cleveland BioLabs Inc
  • Cold Genesys Inc
  • Corvus Pharmaceuticals Inc
  • CytomX Therapeutics Inc
  • Cytori Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Eleven Biotherapeutics Inc
  • Eli Lilly and Co
  • Elsalys Biotech SAS
  • EpiThany Inc
  • Esperance Pharmaceuticals Inc
  • Exelixis Inc
  • Exicure Inc
  • F. Hoffmann-La Roche Ltd
  • Five Prime Therapeutics Inc
  • Gene Signal International SA
  • Genentech Inc
  • Genmab A/S
  • GlaxoSmithKline Plc
  • H3 Biomedicine Inc
  • Hamlet Pharma AB
  • Hanmi Pharmaceuticals Co Ltd
  • HitGen LTD
  • Horizon Pharma Plc
  • Immunocore Ltd
  • Immunomedics Inc
  • Immupharma Plc
  • Imugene Ltd
  • Incanthera Ltd
  • Incyte Corp
  • Innovation Pharmaceuticals Inc
  • InteRNA Technologies BV
  • Iovance Biotherapeutics Inc
  • Johnson & Johnson
  • Kite Pharma Inc
  • Laboratoires Pierre Fabre SA
  • LipoMedix Pharmaceutical Inc
  • Loxo Oncology Inc
  • Lycera Corp
  • MTG Biotherapeutics Inc
  • MacroGenics Inc
  • Marina Biotech Inc
  • MaxiVAX SA
  • MedImmune LLC
  • Medicenna Therapeutics Corp
  • Merck & Co Inc
  • Mirati Therapeutics Inc
  • Moleculin Biotech Inc
  • NanoCarrier Co Ltd
  • NantKwest Inc
  • Nektar Therapeutics
  • Novartis AG
  • OncoTherapy Science Inc
  • Oncovir Inc
  • Ono Pharmaceutical Co Ltd
  • Optimum Therapeutics LLC
  • Oxford BioTherapeutics Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Philogen SpA
  • Pieris Pharmaceuticals Inc
  • Plexxikon Inc
  • Polaris Pharmaceuticals Inc
  • Provecs Medical GmbH (Inactive)
  • Provectus Biopharmaceuticals Inc
  • PsiOxus Therapeutics Ltd
  • Rexahn Pharmaceuticals Inc
  • Samyang Holdings Corp
  • Sanofi
  • Sareum Holdings Plc
  • Shionogi & Co Ltd
  • Sierra Oncology Inc
  • Sillajen Biotherapeutics
  • Sitka Biopharma Inc
  • Sorrento Therapeutics Inc
  • Spectrum Pharmaceuticals Inc
  • Stemline Therapeutics Inc
  • Sun Pharma Advanced Research Company Ltd
  • Taiwan Liposome Company Ltd
  • Taris Biomedical LLC
  • Theralase Technologies Inc
  • Tocagen Inc
  • Tolero Pharmaceuticals Inc
  • Transgene SA
  • UroGen Pharma Ltd
  • Vaccibody AS
  • Vakzine Projekt Management GmbH
  • Vault Pharma Inc
  • Vaxeal Holding SA
  • Vaxiion Therapeutics Inc
  • Viralytics Ltd
  • Vyriad Inc
  • Zymeworks Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll